

9-2022

Defining the Role of Powassan Virus in Evading Host Antiviral Immunity (September 2022)

Melissa Molho, PhD

Thomas Jefferson University, melissa.molhomedina@jefferson.edu

Holly Ramage, PhD

Thomas Jefferson University, holly.ramage@jefferson.edu

Follow this and additional works at: <https://jdc.jefferson.edu/miposters>



Part of the [Medical Microbiology Commons](#), and the [Virus Diseases Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Molho, PhD, Melissa and Ramage, PhD, Holly, "Defining the Role of Powassan Virus in Evading Host Antiviral Immunity (September 2022)" (2022). *Department of Microbiology and Immunology Posters*. 1. <https://jdc.jefferson.edu/miposters/1>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Microbiology and Immunology Posters by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Defining the Role of Powassan Virus in Evading Host Antiviral Immunity

Melissa Molho, PhD and Holly Ramage, PhD

Department of Microbiology and Immunology, Thomas Jefferson University

Transcriptomic analysis of POWV-infected HMC3 cell lines revealed significant induction of Type I interferons, Type III interferons and several IFN-stimulated genes (ISGs) that have not been previously associated with antiviral activity against POWV. See Table 1.

BACKGROUND

Powassan Virus (POWV) is an emerging neurotropic flavivirus transmitted to humans through the bite of an infected tick. Currently, there is no specific antiviral treatment nor approved vaccine for POWV. During infection, many interferon-independent host proteins and pathways sense and respond to viral infection. Flaviviruses have evolved multiple mechanisms to counteract host antiviral programs, often with individual viral proteins mediating this antagonism. However, it has not been determined if these mechanisms are conserved across diverse flaviviruses.

OBJECTIVES

- Identify the antiviral factors in the Central Nervous System (CNS) controlling POWV infection.
- Identify POWV proteins that antagonize expression of Type I interferons and ISGs.

METHODS

- Evaluate POWV infection levels in CNS cell lines.
- Infection of Human microglial cell line (HMC3) with POWV for 24 and 48 h.
- Transcriptomic analysis from HMC3 cells infected with POWV for 48 h.
- Firefly assay with luciferase reporter vector IFN β (Type I IFN) and POWV protein expression vector.




Figure 3. Induction of host genes in HMC3 cells in response to POWV infection. The Log₂ fold change of infected vs. uninfected gene expression is shown on the x-axis. The -Log₁₀ of the adjusted p-value for expression of each gene is shown on the y-axis. Genes that are significantly regulated are indicated in red. Upregulated genes of interest are labeled.

RESULTS




Figure 1. Infection of indicated cell lines with POWV LB. Cells were infected for 48 hours. POWV infection was detected via immunofluorescence using an antibody recognizing the POWV E protein. The cell nuclei were stained with Hoechst.

Figure 2. Infection of HMC3 cell lines with POWV. Relative POWV quantified by qRT-PCR is indicated on the y-axis. Cells were infected for 24 and 48 hours. POWV RNA was normalized to 18S rRNA. Also shown is an uninfected control.

Gene	Log 2-fold change	Adjusted p-value
IFNL1	5.072360524	1.31E-118
IFNL2	3.367760191	1.35E-44
IFIT2	2.030740493	4.07E-15
IFIT1	3.49398642	3.66E-76
IFNB1	4.492852713	1.42E-88
IFNL3	2.482924943	7.25E-23
ISG20	2.203603061	1.10E-31
HERC5	2.90330216	8.08E-49
IFI6	2.639223283	1.91E-36
ISG15	2.351900211	1.65E-29
IFIT3	2.875465832	5.29E-41
IFIT1	2.711212948	4.91E-42
BST2	2.024979807	3.96E-15
OAS2	3.119912573	6.15E-64

Table 1. Upregulated genes in response to POWV in HMC3 cells. Upregulated ISGs of interest are highlighted in blue.




Figure 4. Plasmids expressing POWV LB prM-E, NS5, or an empty vector control were co-transfected into HMC3 cells with a reporter plasmid expressing Firefly luciferase under the control of the IFN β promoter.

FUTURE GOALS

- Test the antiviral activity of identified upregulated ISGs from our RNA-seq dataset and characterize the restriction mechanisms of these antiviral host factors.
- Identify POWV proteins that antagonize expression of Type I and ISGs and determine the mechanism of inhibition of IFN signaling.




Figure 5. Schematic of Type I interferon signaling pathway.

